Infections were reported in 39% of patients on ixekizumab every four weeks, 38% on ixekizumab every two weeks, and 30% of patients on placebo. Three (2%) serious infections in patients taking ixekizumab every two weeks were reported.
The researchers note that 30% to 40% of patients with PsA fail to respond adequately to TNF inhibitors while others become resistant to treatment or develop safety issues. Based on available data to date, ixekizumab dosed every two or four weeks represents a safe and effective alternative in this patient population, they conclude.
The study was funded by ixekizumab maker Eli Lilly and Company. Several authors reported ties to the company.
Reference
Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate responseto tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 May 24. pii: S0140-6736(17)31429-0. [Epub ahead of print]
